Stability Indicating RP-HPLC Method Development and Validation for Simultaneous Quantification of 15 Organic Impurities of Olmesartan Medoxomil, Amlodipine and Hydrochlorothiazide in Combined Dosage Form
- 11 Downloads
A novel, simple, robust and rapid reversed-phased high performance liquid chromatographic method has been developed for the separation and quantitative determination of the 15 organic impurities of olmesartan medoxomil, amlodipine and hydrochlorothiazide in combined dosage forms. Successful separation of five impurities of olmesartan medoxomil, six impurities of amlodipine and four impurities of hydrochlorothiazide, and degradation products formed under stress conditions, was achieved on Inertsil ODS-3 (100 × 4.6 mm, 3.0 μm) column, using gradient elution. The mobile phase A contains 0.0 2 M phosphate buffer (pH 3.3) and acetonitrile in a ratio of (95:05, v/v%) and mobile phase B contains 0.02 M phosphate buffer (pH 3.3), acetonitrile and methanol in a ratio of (20:60:20, v/v/v%). Flow rate monitored at 1.8 mL min−1, and UV detection carried out at 237 nm. During forced degradation studies, the effect of acid, base, oxidation, UV light and temperature was investigated, showing good resolution between the peaks corresponding to process and degradation-related impurities. The performance of the method was validated according to the present ICH guidelines for specificity, linearity, accuracy, precision, ruggedness and robustness. To the best of our knowledge, this is the first research paper which presents a simple and rapid HPLC method, which separates all impurities of olmesartan medoxomil, amlodipine and hydrochlorothiazide in combined dosage forms.
KeywordsHigh-performance liquid chromatography Impurity Method validation Olmesartan medoxomil Amlodipine besylate Hydrochlorothiazide
The authors of the current work wish to acknowledge the management of Zydus Cadila Healthcare Limited for supporting this work, and are grateful to their colleagues from Analytical Research and Development Laboratories.
This study was not funded by any grants.
Compliance with Ethical Standards
Conflict of interest
The authors declare that there is no conflict regarding publication of this paper.
This article does not contain any studies with human participants/animals performed by any authors.
- 1.O'Neil MJ (2006) The merck index: an encyclopedia of chemicals, drugs, and biologicals, vol 14, pp 83, 827, 1178Google Scholar
- 4.Martindale KP (2005) The extra pharmacopoeia. The Complete Drug Reference 34(3):2005Google Scholar
- 10.Rockville MD (2017) United States pharmacopeia and national formulary (USP 41-NF 36). United States Pharmacopeial Convention. https://online.uspnf.com/uspnf. Accessed 18 Jan 2018
- 11.Celebier M, Altinoz S (2007) Determination of olmesartan medoxomil in tablets by UV–Vis spectrophotometry. Pharmazie 62(6):419–422Google Scholar
- 15.Sharma T, Si SC, Gowrishankar D (2010) Difference spectrophotometric method for the determination of Olmesartan medoxomil in tablets. J Pharm Res 3(7):1553–1555Google Scholar
- 17.Mehulkumar P, Ramesh V, Kumar VV, Srinivas R, Diwan PV (2009) Simultaneous spectroscopic estimation of amlodipine besylate and Olmesartan medoximil in tablet dosage form. Asian J Res Chem 2(2):127–130Google Scholar
- 18.Farouk M, EL-Aziz OA, Hemdanb A, Shehata M (2011) Simple novel spectrophotometric and spectrofluorimetric methods for determination of some antihypertensive Drugs. J Am Sci 7:300–312Google Scholar
- 19.Darwish HW, Bakheit AH, Darwish IA (2012) New spectrofluorimetric methods for the simultaneous determination of olmesartan medoxamil and amlodipine besylate in their combined tablets. Dig J Nanomater Bios 7:1599–1608Google Scholar
- 23.Solanki TB, Shah PA, Patel KG (2014) Central composite design for validation of HPTLC method for simultaneous estimation of olmesartan medoxomil, amlodipine besylate and hydrochlorothiazide in tablets. Indian J Pharm Sci 76(3):179Google Scholar
- 26.Tiwari RN, Shah N, Bhalani V, Mahajan A (2015) LC, MSn and LC–MS/MS studies for the characterization of degradation products of amlodipine. J Pharmaceut Anal 5(1):33–42Google Scholar
- 33.Rao JR, Rajput MP, Yadav SS, Mulla TS, Bharekar VV (2011) Simultaneous quantitation of olmesartan medoxomil, Amlodipine besylate and hydrochlorothiazide in pharmaceutical dosage form by using HPLC. Int J PharmTech Res 3(3):1435–1440Google Scholar
- 36.Hamrapurkar PD, Gadapayale KK (2013) Optimization and validation of RP-HPLC stability indicating method for determination of olmesartan medoxomil and its degraded product. Int J Appl Sci Eng 11(2):137–147Google Scholar
- 39.ICH guideline (Q2A) (R1) (2005) Validation of analytical procedures: text and methodology. http://www.ich.org. Accessed 18 Jan 2019